M. Żotkiewicz

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.

N. Rokutanda, T. Okusaka, V. Breder, 2024, The Lancet. Oncology.

Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.

K. Rau, S. Oh, P. Potemski, 2023, Journal of Clinical Oncology.

68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

V. Guthrie, S. Qin, D. Tougeron, 2022, Annals of Oncology.